SEARCH

SEARCH BY CITATION

References

  • 1
    Atsumi T, Koike T. Clinical relevance of antiprothrombin antibodies. Autoimmun Rev 2002; 1: 4953.
  • 2
    Simmelink MJ, Horbach DA, Derksen RHWM, Meijers JC, Bevers EM, Willems GM, De Groot PG. Complexes of anti-prothrombin antibodies and prothrombin cause lupus anticoagulant activity by competing with the binding of clotting factors for catalytic phospholipid surfaces. Br J Haematol 2001; 113: 6219.
  • 3
    Galli M, Willems GM, Rosing J, Janssen RM, Govers-Riemslag JWP, Comfurius P, Barbui T, Zwaal RFA, Bevers EM. Anti-prothrombin IgG from patients with anti-phospholipid antibodies inhibits the inactivation of factor Va by activated protein C. Br J Haematol 2005; 129: 2407.
  • 4
    Von Landenberg P, Matthias T, Zaech J, Schultz M, Larber M, Blank M, Shoenfeld Y. Antiprothrombin antibodies are associated with pregnancy loss in patients with the antiphospholipid syndrome. Am J Reprod Immunol 2003; 49: 516.
  • 5
    Haj-Yahia S, Sherer Y, Blank M, Kaetsu H, Smolinsky A, Shoenfeld Y. Anti-prothrombin antibodies cause thrombosis in a novel qualitative ex-vivo animal model. Lupus 2003; 12: 3649.
  • 6
    Bizzaro N, Tonutti E, Villalta D, Tampoia M, Tozzoli R. Prevalence and clinical correlation of antiphospholipid-binding protein antibodies in anticardiolipin-negative patients with systemic lupus erythematosus and women with unexplained recurrent miscarriages. Arch Pathol Lab Med 2005; 129: 618.
  • 7
    Tsutsumi A, Hayashi T, Chino Y, Mamura M, Goto D, Matsumoto I, Ito S, Sumida T. Significance of anti-prothrombin antibodies in patients with systemic lupus erythematosus: clinical evaluation of the anti-prothrombin assay and the antiphosphatidylserine/prothrombin assay, and comparison with other antiphospholipid antibody assays. Mod Rheumatol 2006; 16: 15864.
  • 8
    Lakos G, Kiss E, Regeczy N, Tarjan P, Soltesz P, Zeher M, Szucs G, Szakony S, Sigka S, Szegedi G. Anti-prothrombin and anti-annexin V antibodies imply risk of thrombosis in patients with systemic autoimmune diseases. J Rheumatol 2000; 27: 9249.
  • 9
    Nojima J, Kuratsune H, Suehisa E, Futsukaichi Y, Yamanishi H, Machii T, Kitani T, Iwatani Y, Kanakura Y. Anti-prothrombin antibodies combined with lupus anticoagulant activity is an essential risk factor for venous thromboembolism in patients with systemic lupus erythematosus. Br J Haematol 2001; 114: 64754.
  • 10
    Pasquier E, Amiral J, De Saint Martin L, Mottier D. A cross sectional study of antiphospholipid-protein antibodies in patients with venous thromboembolism. Thromb Haemost 2001; 86: 53842.
  • 11
    Muñoz-Rodriguez FJ, Reverter JC, Font J, Tassies D, Cervera R, Espinosa G, Carmona F, Balasch J, Ordinas A, Ingelmo M. Prevalence and clinical significance of anti-prothrombin antibodies in patients with systemic lupus erythematosus or with primary anti-phospholipid syndrome. Haematologica 2000; 85: 6327.
  • 12
    Palosuo T, Virtamo J, Haukka J, Taylor PR, Aho K, Puurunen M, Vaarala O. High antibody levels to prothrombin imply a risk of deep venous thrombosis and pulmonary embolism in middle-aged men. Thromb Haemost 1997; 78: 117882.
  • 13
    Ishikura K, Wada H, Kamikura Y, Hattori K, Fukuzawa T, Yamada N, Nakamura M, Nobori T, Nakano T. High prevalence of anti-prothrombin antibody in patients with deep vein thrombosis. Am J Hematol 2004; 76: 33842.
  • 14
    Nojima J, Kuratsune H, Suehisa E, Futsukaichi Y, Yamanishi H, Machii T, Iwatani Y, Kanakura Y. Association between the prevalence of antibodies to β2-glycoprotein I, prothrombin, protein C, protein S, and annexin V in patients with systemic lupus erythematosus and thrombotic and thrombocytopenic complications. Clin Chem 2001; 47: 100815.
  • 15
    Forastiero R, Martinuzzo ME, Adamczuk Y, Carreras LO. Occurrence of anti-prothrombin and anti-beta2-glycoprotein I antibodies in patients with a history of thrombosis. J Lab Clin Med 1999; 134: 6105.
  • 16
    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 12717.
  • 17
    Vitali C, Bencivelli W, Isenberg DA, Smolen JS, Snaith ML, Sciuto M, Neri R, Bombardieri S. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol 1992; 10: 5417.
  • 18
    McIntyre JA, Wagenknecht DR. Effect of storage conditions on the ELISA activity of antiphospholipid antibodies. Thromb Haemost 1994; 71: 676.
  • 19
    Donohoe S, Mackie IJ, Isenberg D, Machin SJ. Anti-prothrombin antibodies: assay conditions and clinical associations in the anti-phospholipid syndrome. Br J Haematol 2001; 113: 5449.
  • 20
    Harris EN, Hughes GR. Standardising the anti-cardiolipin antibody test. Lancet 1987; 1: 277.
  • 21
    Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, Brey R, Derksen R, Harris EN, Hughes GR, Triplett DA, Khamashta MA. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis Rheum 1999; 42: 130911.
  • 22
    Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemost 1995; 74: 118590.
  • 23
    Triplett DA, Boffa MC. Lupus anticoagulant: detection, standardization and heterogeneity. In: AshersonRA, CerveraR, PietteJ-C, ShoenfeldY, eds. The Antiphospholipid Syndrome II. Autoimmune Thrombosis. Amsterdam: Elsevier, 2002: 238.
  • 24
    Galli M, Luciani D, Bertolini G, Barbui T. Anti-β2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003; 102: 271723.
  • 25
    Galli M. Antiphospholipid syndrome: association between laboratory tests and clinical practice. Pathophysiol Haemost Thromb 2004; 33: 24955.
  • 26
    Forastiero R, Martinuzzo M, Pombo G, Puente D, Rossi A, Celebrin L, Bonaccorso S, Aversa L. A prospective study of antibodies to β2-glycoprotein I and prothrombin, and risk of thrombosis. Thromb Haemost 2005; 3: 12318.
  • 27
    Vaarala O, Puurunen M, Manttari M, Manninen V, Aho K, Palosuo T. Antibodies to prothrombin imply a risk of myocardial infarction in middle-aged men. Thromb Haemost 1996; 75: 4569.
  • 28
    Arnout J, Boon D, Vandervoort P, Vanrusselt M, Vermylen J. A monoclonal antibody against prothrombin fragment 2 behaves like a lupus anticoagulant. Lupus 2002; 11: 550.
  • 29
    Atsumi T, Ieko M, Bertolaccini M, Ichikawa K, Tsutsumi A, Matsuura E, Koike T. Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum 2000; 43: 198293.